Dr. Dennis L. Stevens reviews medical content for Healthwise, a
nonprofit organization with a mission to help people make better health
decisions. Dr. Stevens is Chief of Infectious Diseases at the Veterans Affairs
Medical Center in Boise, Idaho. Dr. Stevens is a world-renowned expert in the
field of infectious disease. He is widely published and an active speaker.
Dr. Stevens is a consultant to the Centers for Disease Control on
severe invasive Group A streptococcal infections. He has received the
Infectious Disease Society of America's "Society Citation Award" for his work
with bacterial pathogens.
Healthwise Knowledgebase Topics Reviewed
Professional Affiliations
Selected Publications
- Stevens DL, Wallace RJ, Hamilton SM, Brayant AE (2006).
Successful treatment of staphylococcal toxic shock syndrome with linezolid:
Case report and in vitro evaluation of TSST-1 production in the presence of
antibiotics. Clinical Infectious Diseases, 42(5):
729–730.
- Bryant AE, Bayer CR, Huntington JD, Stevens DL (2006).
Group A streptococcal myonecrosis: Increased vimentin expression following
skeletal muscle injury mediates the binding of S. pyogenes. Journal of Infectious Diseases,
193(12): 1685–1692.
- Nguygen HB, Rivers EP, Abrahamian FM, Moran GJ,
Abraham E, Trzeciak S, Huang DT, Osborn T, Stevens D, Talan DA, ED-SEPSIS
Working Group (2006). Severe sepsis and septic shock: Review of the literature
and emergency department management guidelines. Annals of Emergency Medicine, 48(1): 28–54.
- Aldape MJ, Bryant AE,
Stevens DL (2006). Clostridium sordellii infections:
Epidemiology, clinical findings and current perspectives on diagnosis and
treatment. Clinical Infectious Diseases, 43(11):
1436–1446.
- Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ,
Bryant AE (2007). Impact of sub-inhibitory concentrations of antibiotics on
expression of virulence-associated exotoxin genes in methicillin-sensitive and
methicillin-resistant Staphylococcus aureus.
Journal of Infectious Diseases, 195(2): 202-211.
Financial Disclosure
Dr. Stevens has received research support from Arpida Ltd., Cubist
Pharmaceuticals, F. Hoffman-La Roche Ltd., and Pfizer Inc.